For over a century, heparin has stood as the cornerstone anticoagulant, pivotal in preventing the formation and growth of deleterious blood clots within the cardiovascular system. These clots, though critical for stemming bleeding during injury, pose significant health risks when they obstruct blood flow within vessels or the heart. Despite its effectiveness, heparin’s clinical utility is marred by its propensity to elevate bleeding risks, often resulting in complications from seemingly minor traumas. Recent groundbreaking research, published in ACS Central Science, reveals a novel anticoagulant derived from the snail Camaena cicatricosa, which may revolutionize clot prevention by selectively inhibiting pathological thrombosis while preserving essential blood clotting functions.
Blood clot formation embodies a biological paradox: while hemostatic clots act as vital temporary barriers aiding the repair of injuries such as skin lacerations, thrombi — abnormal, persistent clots — initiate blockages within blood vessels and cardiac chambers that can culminate in stroke, organ damage, or fatal embolisms. Deep vein thrombosis (DVT), characterized by these stubborn clots in the deep veins of the legs, exemplifies such a pathological process. The risk extends beyond the initial clot, as emboli can detach and migrate, causing life-threatening conditions like pulmonary embolism. Conventional treatments rely heavily on systemic anticoagulation using agents like heparin that, while efficacious at preventing thrombi, indiscriminately impair normal clotting and potentiate bleeding hazards.
Motivated by the fundamental need for anticoagulants that selectively target thrombosis without compromising hemostasis, researchers led by Mingyi Wu embarked on an extensive biochemical exploration of molluscan compounds. This undertaking identified a unique glycosaminoglycan, labeled CCG, harvested from Camaena cicatricosa, a terrestrial snail. Glycosaminoglycans are complex polysaccharides that often modulate coagulation cascades; intriguingly, CCG exhibits structural similarities to heparin but notably lacks a specific sugar sequence essential for heparin’s binding to coagulation factors that influence normal clotting. This structural divergence suggested CCG may retain anticoagulant activity with diminished bleeding risk.
Detailed in vitro analyses using human plasma demonstrated that CCG effectively inhibits thrombus formation without impairing hemostatic processes critical for wound healing. This bifurcation of anticoagulant efficacy and preserved hemostasis represents a significant advance beyond existing therapies. Moreover, in a validated murine DVT model, injected CCG significantly lowered thrombus incidence and burden, replicating in vitro findings. Notably, unlike heparin, CCG-treated mice did not show an increased tendency toward hemorrhage, underscoring its therapeutic safety profile and potential for clinical translation.
At the mechanistic level, the investigation revealed that CCG exerts its antithrombotic effect by blocking the assembly of intrinsic factor Xase (iFXase), an enzyme complex instrumental in thrombin generation specifically within thrombosis pathways. Unlike other coagulation factors implicated in both thrombosis and hemostasis, iFXase activity is dispensable for normal bleeding control but crucial for pathological clot propagation. By disassembling this enzymatic complex, CCG impedes thrombus formation selectively, providing a molecular rationale for its lack of bleeding complications.
This targeted inhibition is particularly significant because current anticoagulants such as heparin indiscriminately impair coagulation pathways, including those necessary for physiological hemostasis, driving unwanted bleeding risks. The discovery of CCG, therefore, opens avenues for developing anticoagulant agents that separate the therapeutic objective of thrombosis prevention from the adverse effect of hemorrhage, a longstanding challenge in medicine. Such agents could dramatically improve outcomes for patients at risk of thrombotic events while maintaining safety during invasive procedures or trauma.
Despite compelling initial findings, rigorous clinical evaluation remains essential before translating CCG into approved therapies. Factors such as pharmacodynamics, pharmacokinetics, dosing regimens, potential immunogenicity, and long-term safety profiles necessitate in-depth study. Additionally, nuances of anticoagulant action in diverse patient populations with complex comorbidities will require careful elucidation. Nevertheless, this research establishes a promising platform for next-generation selective anticoagulants derived from natural sources, potentially reshaping the management of thrombotic diseases.
The research team acknowledges multifaceted support from prestigious Chinese scientific foundations and institutions, emphasizing the strategic prioritization of innovative natural products for biomedical application. The intersection of natural product chemistry, biochemistry, and translational medicine showcased in this work exemplifies contemporary approaches toward addressing chronic medical challenges. As natural sources continue to reveal bioactive molecules with therapeutic potential, the story of CCG highlights the importance of biodiversity and traditional knowledge in advancing modern science.
Importantly, this discovery also tests the paradigm that anticoagulant efficacy inevitably necessitates bleeding risk, introducing the possibility that specific molecular targets can be modulated to disaggregate thrombosis from hemostasis. If subsequent research validates and extends these findings, CCG or analogous compounds could supplant or complement current anticoagulants, improving patient safety and quality of life. Tailored anticoagulants might also expand preventive and therapeutic options for conditions such as stroke, myocardial infarction, and pulmonary embolism, which remain leading causes of morbidity and mortality worldwide.
In summary, this breakthrough underscores the power of interdisciplinary research: blending natural product chemistry, molecular biology, and clinical science to conceive innovative therapies. The identification of a snail-derived glycosaminoglycan with selective anticoagulant properties marks a milestone deserving close attention from the medical and scientific communities. Future studies may well harness this molecule’s potential, offering a safer, more precise approach to managing blood clot-related diseases, a vital advance in cardiovascular medicine.
The full abstract and detailed data for this research will be accessible beginning March 18, 2026, through ACS Central Science, providing scholars and clinicians a window into this transformative discovery.
Subject of Research: Glycosaminoglycan compound from the snail Camaena cicatricosa as a selective anticoagulant agent.
Article Title: Snail-derived compound could be a safer anticoagulant compared to heparins
News Publication Date: 18-Mar-2026
Web References:
http://pubs.acs.org/doi/abs/10.1021/acscentsci.5c02230
References: ACS Central Science, DOI: 10.1021/acscentsci.5c02230
Keywords: anticoagulant, heparin, glycosaminoglycan, snail-derived compound, thrombosis, deep vein thrombosis, hemostasis, intrinsic factor Xase, selective inhibition, blood clotting, thrombus, natural product chemistry
Tags: ACS Central Science anticoagulant studyCamaena cicatricosa compoundcardiovascular clot managementdeep vein thrombosis treatmenthemostatic clot preservationheparin bleeding risk reductionnovel anticoagulant researchpathological blood clot preventionpulmonary embolism preventionsafer alternative to heparinselective thrombosis inhibitionsnail-derived anticoagulant
